June 30, 2020 / 11:01 AM / 8 days ago

Zynerba's cannabis-based drug for rare genetic disorder fails study

June 30 (Reuters) - Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary goals of a pivotal trial in patients with a neurological disorder called Fragile X syndrome.

Fragile X syndrome (FXS) is characterized by mild-to-moderate intellectual disability. (Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below